JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Alcon Inc

Fermé

SecteurSoins de santé

84.66 -1.24

Résumé

Variation du prix de l'action

24h

Actuel

Min

84.49

Max

85.68

Chiffres clés

By Trading Economics

Revenu

76M

350M

Ventes

-29M

2.5B

P/E

Moyenne du Secteur

39.031

34.393

Rendement du dividende

0.38

Marge bénéficiaire

14.153

Employés

25,000

EBITDA

-226M

463M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+24.44% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.38%

2.54%

Prochains Résultats

19 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.6B

44B

Ouverture précédente

85.9

Clôture précédente

84.66

Sentiment de l'Actualité

By Acuity

50%

50%

162 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Alcon Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 août 2025, 10:10 UTC

Acquisitions, Fusions, Rachats

Alcon to Buy Staar Surgical for $1.5 Billion

14 mai 2025, 15:56 UTC

Résultats
Principaux Mouvements du Marché

Alcon Shares Fall After Lowering 2025 Outlook

26 mars 2025, 21:22 UTC

Acquisitions, Fusions, Rachats

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mars 2025, 12:36 UTC

Acquisitions, Fusions, Rachats

Alcon to Buy Lensar in Deal Worth Up to $430 Million

8 août 2025, 13:40 UTC

Market Talk
Acquisitions, Fusions, Rachats

Staar Surgical's Top Holder Questions Deal -- Market Talk

5 août 2025, 05:07 UTC

Acquisitions, Fusions, Rachats

Alcon Deal Puts STARR Equity Value at Approximately $1.5 Billion. >ALC.EB

5 août 2025, 05:07 UTC

Acquisitions, Fusions, Rachats

Alcon Will Purchase All Outstanding Shares of STAAR Common Stock for $28 Per Share in Cash >ALC.EB

5 août 2025, 05:07 UTC

Acquisitions, Fusions, Rachats

Alcon Deal Represents 51% Premium to Closing Price of STAAR Common Stock on Aug. 4 >ALC.EB

5 août 2025, 05:07 UTC

Acquisitions, Fusions, Rachats

Alcon Agrees to Acquire STAAR Surgical >ALC STAA

5 août 2025, 05:01 UTC

Acquisitions, Fusions, Rachats

Alcon Agrees To Acquire STAAR Surgical >ALC STAA

7 juil. 2025, 12:00 UTC

Acquisitions, Fusions, Rachats

Alcon To Acquire LumiThera And Its Photobiomodulation Device For The Treatment Of Early And Intermediate Dry Age-Related Macular Degeneration (AMD) >ALC

30 mai 2025, 06:32 UTC

Market Talk
Résultats

Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

22 mai 2025, 20:46 UTC

Acquisitions, Fusions, Rachats

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

13 mai 2025, 20:32 UTC

Résultats

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mai 2025, 20:31 UTC

Résultats

Alcon 1Q Sales $2.45B >ALC.EB

13 mai 2025, 20:30 UTC

Résultats

Alcon 1Q Rev $2.47B >ALC.EB

13 mai 2025, 20:30 UTC

Résultats

Alcon 1Q EPS 70c >ALC.EB

8 avr. 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

26 mars 2025, 21:55 UTC

Market Talk
Acquisitions, Fusions, Rachats

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mars 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mars 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mars 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mars 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mars 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mars 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mars 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

Alcon Acquires Majority Interest in Aurion Biotech

24 mars 2025, 12:21 UTC

Acquisitions, Fusions, Rachats

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mars 2025, 12:05 UTC

Acquisitions, Fusions, Rachats

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mars 2025, 12:05 UTC

Acquisitions, Fusions, Rachats

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mars 2025, 12:04 UTC

Acquisitions, Fusions, Rachats

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

Comparaison

Variation de prix

Alcon Inc prévision

Objectif de Prix

By TipRanks

24.44% hausse

Prévisions sur 12 Mois

Moyen 106.71 USD  24.44%

Haut 123.933 USD

Bas 84 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

15 ratings

12

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

95.77 / 97.61Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

162 / 374Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.